Neeraj Agarwal, MD on TITAN and PFS2 Study: How This Affects Clinicians @neerajaiims of @huntsmancancer #PFS2 #TITAN #prostatecancer

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC affecting clinicians and treatment.

#prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer